Serum levels of total acid phosphatase, prostatic acid phosphatase, total and free prostate-specific antigen in patients within chronic hemodialysis program

Gümüş B., Lekili M., Uyanik B., TEMELTAŞ G., Büyüksu T., KÜRŞAT S.

Brazilian Journal of Urology, cilt.27, sa.2, ss.133-135, 2001 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 2
  • Basım Tarihi: 2001
  • Dergi Adı: Brazilian Journal of Urology
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.133-135
  • Anahtar Kelimeler: Cancer, Hemodialysis, Prostate, Prostatic markers
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Objective: To investigate the effect of terminal renal failure with chronic hemodialysis on prostatic disease markers [total acid phosphatase (TAP), prostatic acid phosphatase (PAP), prostate-specific antigen (PSA) and free prostate-specific antigen (fPSA)]. Patients and Method: Total acid phosphatase (TAP), prostatic acid phosphatase (PAP), prostate-specific antigen (PSA) and free prostate-specific antigen (fPSA) were measured in 28 patients over 40 years of age on terminal renal failure with chronic hemodialysis. Correlation was calculated between the dialysis duration and prostatic disease marker levels. Results: There was no evidence of artefactual elevation of prostatic disease markers. TAP, PAP, PSA and fPSA levels were in the normal range in all of the patients. However, PSA and fPSA levels decreased as the dialysis duration increased. Conclusion: Prostatic disease markers were useful in the routine screening of men receiving long-term dialysis, but the clinicians should be on alert when the dialysis duration increases.